Abstrakt

Approaches to identifying clinically relevant biomarkers for neurodegenerative disease.

Goldberg Kives

The development of efficient disease-modifying therapies and the oversight of their use are both made possible by the availability of biomarkers for neurodegenerative diseases. Designing clinical trials and observational studies with positron emission tomography methods to detect amyloid- and tau-pathology in Alzheimer's disease has become more and more common. The development of readily available and affordable blood-based biomarkers that can identify the same pathologies associated with Alzheimer's disease in recent years has the potential to completely alter how the disease is diagnosed worldwide. Blood-based indicators of general neurodegeneration and glial activation, as well as relevant biomarkers for -syncline pathology in Parkinson's disease, are also developing. An overview of the most recent developments in the study of biomarkers for neurodegenerative diseases is provided in this review. Future directions for implementation are discussed.